Efficacy of different doses of 12-month Interferon alfa therapy in patients with HBeAg negative chronic hepatitis B: A randomized trial (EN)

Hatzakis, A.

Tassopoulos, N. C.

Vafiadou, Irini

Papatheodoridis, G. V.

Delladetsima, Ioanna

The best interferon-alfa (IFNα) regimen for HBeAg negative chronic hepatitis B has not been established yet. We evaluated the efficacy of three regimens of IFNα in 75 patients with histologically documented HBeAg negative chronic hepatitis B, who were randomly allocated to receive IFNα-2b thrice weekly in a dose of: 3MU for 12 months (Group A, n=25); 5 MU for 6 months and 3 MU for another 6 months (Group B, n=25); and 3 MU for 6 months and 1 MU for another 6 months (Group C, n=25). Initial biochemical response was observed in 71% of the 75 patients and initial virological response (undetectable serum HBV DNA by bDNA assay) in 38% of the patients with pre-treatment detectable serum HBV DNA. The decline of HBV DNA levels at the end of therapy was significant in group A (P=0.02) or B (P=0.004), but not in group C. Sustained biochemical and virological response rates (at 6 months after the end of therapy) were 35% and 22% respectively, without any significant difference among the three groups. There was a significant improvement in the grading (P (EN)

info:eu-repo/semantics/article

info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία

Annals of Gastroenterology

Αγγλική γλώσσα

2007-04-12

http://www.annalsgastro.gr/index.php/annalsgastro/article/view/542

Hellenic Society of Gastroenterology (EN)

1792-7463

1108-7471

Annals of Gastroenterology; Volume 19, No 4 (2006) (EN)